精华制药(002349) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥334,493,742.71, representing a 9.83% increase compared to ¥304,542,238.53 in the same period last year[9] - The net profit attributable to shareholders for Q1 2021 was ¥56,677,913.02, up 5.07% from ¥53,945,183.55 in the previous year[9] - The basic earnings per share for Q1 2021 was ¥0.0696, a 4.98% increase from ¥0.0663 in the same period last year[9] - The company reported a decrease of 1.37% in net profit after deducting non-recurring gains and losses, totaling ¥56,467,371.36 compared to ¥57,253,335.34 in the previous year[9] - The company reported a total comprehensive income of ¥62,561,935.39, compared to ¥54,338,530.47 from the previous period[63] - Net profit for the current period was ¥62,561,935.39, representing a 15.5% increase from ¥54,338,530.47 in the previous period[61] Cash Flow and Liquidity - The net cash flow from operating activities increased by 39.81% to ¥67,386,448.72, compared to ¥48,197,106.08 in the same period last year[9] - The company's cash and cash equivalents increased to ¥606,292,455.51 as of March 31, 2021, up from ¥581,318,648.60 at the end of 2020, representing a growth of 4.67%[39] - Cash flow from operating activities increased to 67,386,448.72 from 48,197,106.08, representing a growth of approximately 39.5%[75] - Cash and cash equivalents at the end of the period reached 600,739,319.32, compared to 295,650,387.20 at the end of the previous period, marking an increase of approximately 102.6%[78] - The net increase in cash and cash equivalents was -$8,199,298.78, with a beginning balance of $167,317,758.43, resulting in an ending balance of $159,118,459.65[82] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,160,957,880.85, a slight increase of 0.16% from ¥3,156,027,189.46 at the end of the previous year[9] - The net assets attributable to shareholders increased by 2.72% to ¥2,164,817,838.44 from ¥2,107,504,709.65 at the end of the previous year[9] - Current liabilities totaled approximately $530.74 million, a slight increase from $528.48 million[45] - Total liabilities decreased to approximately $610.72 million from $669.29 million[45] - Total non-current assets decreased slightly to approximately $1.73 billion from $1.74 billion[42] Expenses and Investments - Research and development expenses rose to ¥14,562,216.19 in Q1 2021, a 47.10% increase compared to ¥9,899,701.65 in Q1 2020, due to increased investment in technological innovation[22] - The company reported a significant increase in other income, which reached ¥2,376,892.74 in Q1 2021, up 438.72% from ¥441,208.68 in Q1 2020, primarily due to increased government subsidies[22] - The company reported a decrease in investment income, which fell by 56.24% to ¥1,168,845.34 from ¥2,670,961.73, primarily due to reduced profits from an associated company[22] - The company incurred a credit impairment loss of 225,720.48, down from 689,114.10, reflecting a decrease of approximately 67.2%[72] Shareholder Information - The top shareholder, Nantong Industrial Holdings Group, held 34.29% of the shares, with a total of 286,592,160 shares[14] - The company reported an increase in undistributed profits to approximately $371.25 million from $314.58 million[48] - Total equity attributable to shareholders increased to approximately $2.16 billion from $2.11 billion[48] Other Information - The company did not report any non-recurring gains or losses that were classified as regular gains or losses during the reporting period[12] - The first quarter report for 2021 was not audited[86]